P53 Codon 72 Polymorphism and Breast Cancer Risk: A Meta-analysis

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2013 Jun 6

PMID 23737888

Citations 15

Authors

Jing Hou

Yuan Jiang

Wenru Tang

Shuting Jia

Affiliations

Soon will be listed here.

Abstract

p53 is a tumor suppressor gene and plays important roles in the etiology of breast cancer. Studies have produced conflicting results concerning the role of p53 codon 72 polymorphism (G>C) on the risk of breast cancer; therefore, a meta-analysis was performed to estimate the association between the p53 codon 72 polymorphism and breast cancer. Screening of the PubMed database was conducted to identify relevant studies. Studies containing available genotype frequencies of the p53 codon 72 polymorphism were selected and a pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the association. Sixty-one published studies, including 28,539 breast cancer patients and 32,788 controls were identified. The results suggest that variant genotypes are not associated with breast cancer risk (Pro/Pro + Arg/Pro vs. Arg/Arg: OR=1.016, 95% CI=0.931-1.11, P=0.722). The symmetric funnel plot, Egger's test (P=0.506) and Begg's test (P=0.921) were all suggestive of the lack of publication bias. This meta-analysis suggests that the p53 codon 72 Pro/Pro + Arg/Pro genotypes are not associated with an increased risk of breast cancer. To validate the association between the p53 codon 72 polymorphism and breast cancer, further studies with larger numbers of participants worldwide are required.

Citing Articles

Impact of Interaction between Single Nucleotide Polymorphism of XRCC1, XRCC2, XRCC3 with Tumor Suppressor Tp53 Gene Increases Risk of Breast Cancer: A Hospital Based Case-Control Study.

Datkhile K, Gudur R, Bhosale S, Durgawale P, Jagdale N, More A Asian Pac J Cancer Prev. 2023; 24(9):3065-3075.

PMID: 37774058 PMC: 10762731. DOI: 10.31557/APJCP.2023.24.9.3065.

TP53 (rs1042522, rs28934571) and TP21 (rs1801270, rs1059234) Polymorphisms and Risk of Breast Cancer among Rural Women of Maharashtra: Findings from a Hospital Based Case- Control Study.

Datkhile K, Bhosale S, Durgawale P, Jagdale N, More A, Gudur R Asian Pac J Cancer Prev. 2023; 24(5):1611-1619.

PMID: 37247280 PMC: 10495895. DOI: 10.31557/APJCP.2023.24.5.1611.

Association Between the Polymorphisms and Breast Cancer Risk: An Updated Meta-Analysis.

Zhao L, Yin X, Qin J, Wang W, He X Front Genet. 2022; 13:807466.

PMID: 35571038 PMC: 9091657. DOI: 10.3389/fgene.2022.807466.

p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.

Diakite B, Kassogue Y, Dolo G, Wang J, Neuschler E, Kassogue O BMC Med Genet. 2020; 21(1):206.

PMID: 33076844 PMC: 7574232. DOI: 10.1186/s12881-020-01133-8.

Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis.

Jafrin S, Aziz M, Anonna S, Akter T, Naznin N, Reza S Asian Pac J Cancer Prev. 2020; 21(6):1511-1519.

PMID: 32592343 PMC: 7568897. DOI: 10.31557/APJCP.2020.21.6.1511.

References

Huang X, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M . Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2003; 10(4):307-11. DOI: 10.1007/BF02967650. View

Schmidt M, Reincke S, Broeks A, Braaf L, Hogervorst F, Tollenaar R . Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 2007; 67(19):9584-90. DOI: 10.1158/0008-5472.CAN-07-0738. View

Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R . Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008; 8:32. PMC: 2254432. DOI: 10.1186/1471-2407-8-32. View

BENNETT W, Hussain S, Vahakangas K, Khan M, Shields P, Harris C . Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 1999; 187(1):8-18. DOI: 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y. View

Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N . Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 1986; 6(12):4650-6. PMC: 367250. DOI: 10.1128/mcb.6.12.4650-4656.1986. View

Khadang B, Fattahi M, Talei A, Samsami Dehaghani A, Ghaderi A . Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 2007; 173(1):38-42. DOI: 10.1016/j.cancergencyto.2006.09.010. View

Brosh R, Rotter V . When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9(10):701-13. DOI: 10.1038/nrc2693. View

Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S . Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993; 14(6):1085-9. DOI: 10.1093/carcin/14.6.1085. View

Papadakis E, Dokianakis D, Spandidos D . p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun. 2000; 3(6):389-92. DOI: 10.1006/mcbr.2000.0241. View

10.

Koh W, van den Berg D, Jin A, Wang R, Yuan J, Yu M . Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore. Breast Cancer Res Treat. 2011; 130(3):1011-9. PMC: 3404431. DOI: 10.1007/s10549-011-1680-2. View

11.

Kalemi T, Lambropoulos A, Gueorguiev M, Chrisafi S, T Papazisis K, Kotsis A . The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett. 2005; 222(1):57-65. DOI: 10.1016/j.canlet.2004.11.025. View

12.

Cox D, Deer D, Guo Q, Tworoger S, Hankinson S, Hunter D . The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control. 2007; 18(6):621-5. DOI: 10.1007/s10552-007-9004-x. View

13.

Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S . No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci. 2004; 1010:764-70. DOI: 10.1196/annals.1299.137. View

14.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

15.

Ravi R, Mookerjee B, Bhujwalla Z, Sutter C, Artemov D, Zeng Q . Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000; 14(1):34-44. PMC: 316350. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

17.

Zhou Y, Li N, Zhuang W, Liu G, Wu T, Yao X . P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007; 121(7):1481-6. DOI: 10.1002/ijc.22833. View

18.

Dumont P, Leu J, Della Pietra 3rd A, George D, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-65. DOI: 10.1038/ng1093. View

19.

Katiyar S, Thelma B, Murthy N, Hedau S, Jain N, Gopalkrishna V . Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem. 2003; 252(1-2):117-24. DOI: 10.1023/a:1025546610920. View

20.

Garcia-Closas M, Kristensen V, Langerod A, Qi Y, Yeager M, Burdett L . Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer. 2007; 121(11):2532-8. DOI: 10.1002/ijc.22985. View